Literature DB >> 8862288

Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.

W D Leslie1, D N Abrams, C R Greenberg, D Hobson.   

Abstract

UNLABELLED: Although 123I-IBZM is widely used as a D2 receptor imaging agent, image quality is compromised by a relatively low target-to-nontarget ratio. Animal studies suggest that 123I-epidepride (Kd 0.024 nM) may be superior to 123I-IBZM, but this agent has not been systematically studied in humans.
METHODS: We directly compared 123I-epidepride and 123I-IBZM in five normal volunteers (age range 30-58 yr, mean 43 yr). Brain SPECT imaging was performed 2 hr after the 123I-IBZM injection (average dose 153 MBq). Iodine-123-epidepride scans were performed 1 hr (n = 3), 2 hr (n = 5) and 3 hr (n = 3) postinjection (average dose 149 MBq).
RESULTS: Both radiopharmaceuticals were well tolerated. Iodine-123-epidepride provided excellent visualization of the striatum. Percent specific striatum uptake at 2 hr (71.7 +/- 4.9%) was much greater than with 123I-IBZM (32.6 +/- 5.3%, p < 0.01).
CONCLUSION: Iodine-123-epidepride is a new D2 receptor agent that exhibits excellent neuroimaging properties and has a much higher affinity for striatal uptake than 123I-IBZM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862288

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

Review 1.  Receptor imaging in the diagnosis and treatment of pituitary tumors.

Authors:  D J Kwekkeboom; W W de Herder; E P Krenning
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.

Authors:  P Tibbo; P H Silverstone; A J McEwan; J Scott; A Joshua; K Golberg
Journal:  J Psychiatry Neurosci       Date:  1997-01       Impact factor: 6.186

Review 3.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT.

Authors:  Stergios Tsartsalis; Benjamin B Tournier; Philippe Millet
Journal:  EJNMMI Res       Date:  2020-06-16       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.